It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Psoraleae Fructus (PF) is a widely-used herb with diverse pharmacological activities, while its related hepatic injuries have aroused public concerns. In this work, a systematic approach based on RNA sequencing (RNA-seq), high-content screening (HCS) and molecular docking was developed to investigate the potential mechanism and identify major phytochemicals contributed to PF-induced hepatotoxicity. Animal experiments proved oral administration of PF water extracts disturbed lipid metabolism and promoted hepatic injuries by suppressing fatty acid and cholesterol catabolism. RNA-seq combined with KEGG enrichment analysis identified mitochondrial oxidative phosphorylation (OXPHOS) as the potential key pathway. Further experiments validated PF caused mitochondrial structure damage, mtDNA depletion and inhibited expressions of genes engaged in OXPHOS. By detecting mitochondrial membrane potential and mitochondrial superoxide, HCS identified bavachin, isobavachalcone, bakuchiol and psoralidin as most potent mitotoxic compounds in PF. Moreover, molecular docking confirmed the potential binding patterns and strong binding affinity of the critical compounds with mitochondrial respiratory complex. This study unveiled the underlying mechanism and phytochemicals in PF-induced liver injuries from the view of mitochondrial dysfunction.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Tianjin University of Traditional Chinese Medicine, Tianjin, People’s Republic of China (GRID:grid.410648.f) (ISNI:0000 0001 1816 6218); Beijing Institute of Radiation Medicine, Department of Pharmaceutical Sciences, Beijing, People’s Republic of China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839)
2 Beijing Institute of Radiation Medicine, Department of Pharmaceutical Sciences, Beijing, People’s Republic of China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839)
3 Beijing Institute of Radiation Medicine, Department of Pharmaceutical Sciences, Beijing, People’s Republic of China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); Beijing University of Technology, Faculty of Environment and Life Science, Beijing, People’s Republic of China (GRID:grid.28703.3e) (ISNI:0000 0000 9040 3743)
4 Beijing Institute of Radiation Medicine, Department of Pharmaceutical Sciences, Beijing, People’s Republic of China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); Guangdong Pharmaceutical University, School of Pharmacy, Guangzhou, People’s Republic of China (GRID:grid.411847.f) (ISNI:0000 0004 1804 4300)